Header Logo

Connection

DAVID GRAHAM to Drug Resistance, Bacterial

Back to Details
This is a "connection" page, showing publications DAVID GRAHAM has written about Drug Resistance, Bacterial.
DAVID GRAHAM
Connection Strength
6.937
Drug Resistance, Bacterial
  1. Overcoming the effects of increasing antimicrobial resistance on Helicobacter pylori therapy. Expert Rev Gastroenterol Hepatol. 2024 Nov; 18(11):705-711.
    View in: PubMed
    Score: 0.732
  2. National and Regional US Antibiotic Resistance to Helicobacter pylori: Lessons From a Clinical Trial. Gastroenterology. 2021 07; 161(1):342-344.e1.
    View in: PubMed
    Score: 0.567
  3. Hp-normogram (normo-graham) for Assessing the Outcome of H. pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype. Helicobacter. 2016 Apr; 21(2):85-90.
    View in: PubMed
    Score: 0.391
  4. Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clin Gastroenterol Hepatol. 2015 Sep; 13(9):1616-24.
    View in: PubMed
    Score: 0.371
  5. Detection of clarithromycin resistance in Helicobacter pylori following noncryogenic storage of rapid urease tests for 30 days. J Dig Dis. 2012 Jan; 13(1):54-9.
    View in: PubMed
    Score: 0.299
  6. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2010 Jan; 8(1):36-41.e1.
    View in: PubMed
    Score: 0.256
  7. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008 Jun; 5(6):321-31.
    View in: PubMed
    Score: 0.231
  8. Response to: a true point-of-care molecular testing method for tailored therapy for Helicobacter pylori eradication. Expert Rev Gastroenterol Hepatol. 2023 03; 17(3):311.
    View in: PubMed
    Score: 0.162
  9. How widespread and convenient H. pylori susceptibility testing will result in pharmacological opportunities. Expert Rev Gastroenterol Hepatol. 2023 Jan; 17(1):1-7.
    View in: PubMed
    Score: 0.160
  10. Antimicrobial Susceptibility Testing for Helicobacter pylori Is Now Widely Available: When, How, Why. Am J Gastroenterol. 2022 04 01; 117(4):524-528.
    View in: PubMed
    Score: 0.152
  11. Comparable Results of Helicobacter pylori Antibiotic Resistance Testing of Stools vs Gastric Biopsies Using Next-Generation Sequencing. Gastroenterology. 2022 06; 162(7):2095-2097.e2.
    View in: PubMed
    Score: 0.151
  12. Comparison of Culture With Antibiogram to Next-Generation Sequencing Using Bacterial Isolates and Formalin-Fixed, Paraffin-Embedded Gastric Biopsies. Gastroenterology. 2021 11; 161(5):1433-1442.e2.
    View in: PubMed
    Score: 0.145
  13. Recent Developments Pertaining to H. pylori Infection. Am J Gastroenterol. 2021 01 01; 116(1):1-3.
    View in: PubMed
    Score: 0.139
  14. Classification system for Helicobacter pylori therapies: Compared and contrasted to traditional infectious disease therapy. Helicobacter. 2021 Feb; 26(1):e12773.
    View in: PubMed
    Score: 0.138
  15. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. J Gastroenterol Hepatol. 2021 May; 36(5):1159-1163.
    View in: PubMed
    Score: 0.137
  16. Current and Future Treatment of Helicobacter pylori Infections. Adv Exp Med Biol. 2019; 1149:211-225.
    View in: PubMed
    Score: 0.121
  17. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018 09; 16(9):679-687.
    View in: PubMed
    Score: 0.118
  18. Lessons From Using Culture-Guided Treatment After Referral for Multiple Treatment Failures for Helicobacter pylori Infection. Clin Gastroenterol Hepatol. 2018 09; 16(9):1531-1532.
    View in: PubMed
    Score: 0.113
  19. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018 Jan; 33(1):37-56.
    View in: PubMed
    Score: 0.113
  20. Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut. 2017 12; 66(12):2043-2046.
    View in: PubMed
    Score: 0.111
  21. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol. 2017 07; 14(7):383-384.
    View in: PubMed
    Score: 0.108
  22. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Dig Dis Sci. 2016 11; 61(11):3215-3220.
    View in: PubMed
    Score: 0.104
  23. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogot?-Colombia (2009-2014). PLoS One. 2016; 11(7):e0160007.
    View in: PubMed
    Score: 0.102
  24. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016 06; 14(6):577-85.
    View in: PubMed
    Score: 0.101
  25. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. World J Gastroenterol. 2015 Dec 07; 21(45):12954-62.
    View in: PubMed
    Score: 0.098
  26. Helicobacter pylori: New Thoughts and Practices. Gastroenterol Clin North Am. 2015 Sep; 44(3):xv-xvi.
    View in: PubMed
    Score: 0.096
  27. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol Clin North Am. 2015 Sep; 44(3):537-63.
    View in: PubMed
    Score: 0.095
  28. Roadmap for elimination of gastric cancer in Korea. Korean J Intern Med. 2015 Mar; 30(2):133-9.
    View in: PubMed
    Score: 0.093
  29. Improved allele-specific PCR assays for detection of clarithromycin and fluoroquinolone resistant of Helicobacter pylori in gastric biopsies: identification of N87I mutation in GyrA. Diagn Microbiol Infect Dis. 2015 Apr; 81(4):251-5.
    View in: PubMed
    Score: 0.092
  30. Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. World J Gastroenterol. 2014 Mar 28; 20(12):3343-9.
    View in: PubMed
    Score: 0.087
  31. Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance. Curr Pharm Des. 2014; 20(28):4510-6.
    View in: PubMed
    Score: 0.086
  32. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol. 2013 Oct; 25(10):1134-40.
    View in: PubMed
    Score: 0.084
  33. Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogot? D.C., Colombia. J Microbiol. 2013 Aug; 51(4):448-52.
    View in: PubMed
    Score: 0.084
  34. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):177-86.e3; Discussion e12-3.
    View in: PubMed
    Score: 0.082
  35. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013 Oct; 18(5):373-7.
    View in: PubMed
    Score: 0.082
  36. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J Clin Gastroenterol. 2011 Apr; 45(4):309-13.
    View in: PubMed
    Score: 0.071
  37. Empiric therapies for Helicobacter pylori infections. CMAJ. 2011 Jun 14; 183(9):E506-8.
    View in: PubMed
    Score: 0.070
  38. Helicobacter pylori infection in India from a western perspective. Indian J Med Sci. 2010 Sep; 64(9):423-40.
    View in: PubMed
    Score: 0.068
  39. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010 Aug; 59(8):1143-53.
    View in: PubMed
    Score: 0.067
  40. Clinical practice: diagnosis and evaluation of dyspepsia. J Clin Gastroenterol. 2010 Mar; 44(3):167-72.
    View in: PubMed
    Score: 0.066
  41. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008; 68(6):725-36.
    View in: PubMed
    Score: 0.057
  42. Helicobacter pylori eradication and its effect on iron stores: a reappraisal. J Infect Dis. 2006 Sep 01; 194(5):714; author reply 715-6.
    View in: PubMed
    Score: 0.052
  43. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori. Aliment Pharmacol Ther. 2005 Jan 15; 21(2):165-8.
    View in: PubMed
    Score: 0.046
  44. Effects of amoxicillin dosage on cure rate, gut microbiota, and?antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial. Lancet Microbe. 2025 Mar; 6(3):100975.
    View in: PubMed
    Score: 0.046
  45. Helicobacter pylori infection: diagnosis and treatment. Expert Rev Anti Infect Ther. 2004 Aug; 2(4):599-610.
    View in: PubMed
    Score: 0.045
  46. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis. 2004 Jun; 36(6):384-7.
    View in: PubMed
    Score: 0.044
  47. The QUADRATE study: a proposal for a change in the reporting of pharmaceutical supported trials. Gastroenterology. 2003 Aug; 125(2):639; author reply 640-1.
    View in: PubMed
    Score: 0.042
  48. Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe. Am J Gastroenterol. 2023 02 01; 118(2):269-275.
    View in: PubMed
    Score: 0.039
  49. Environmental antimicrobial resistance is associated with faecal pollution in Central Thailand's coastal aquaculture region. J Hazard Mater. 2021 08 15; 416:125718.
    View in: PubMed
    Score: 0.035
  50. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020 12; 69(12):2093-2112.
    View in: PubMed
    Score: 0.034
  51. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter. 2020 Aug; 25(4):e12692.
    View in: PubMed
    Score: 0.033
  52. Prevalence of Antibiotic Resistance in Helicobacter pylori: A?Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018 11; 155(5):1372-1382.e17.
    View in: PubMed
    Score: 0.029
  53. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 01; 66(1):6-30.
    View in: PubMed
    Score: 0.026
  54. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter. 2014 Jun; 19(3):207-13.
    View in: PubMed
    Score: 0.022
  55. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol. 2013 08; 10(8):495-500.
    View in: PubMed
    Score: 0.021
  56. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007 Jun; 56(6):772-81.
    View in: PubMed
    Score: 0.013
  57. Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. Aliment Pharmacol Ther. 2006 Jan 15; 23(2):295-301.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.